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Pathological mechanisms and therapeutic outlooks for
arthrofibrosis
Kayley M. Usher1, Sipin Zhu2, Georgios Mavropalias3, John A. Carrino4, Jinmin Zhao5,6 and Jiake Xu1,5
Arthrofibrosis is a fibrotic joint disorder that begins with an inflammatory reaction to insults such as injury, surgery and infection.
Excessive extracellular matrix and adhesions contract pouches, bursae and tendons, cause pain and prevent a normal range of joint
motion, with devastating consequences for patient quality of life. Arthrofibrosis affects people of all ages, with published rates
varying. The risk factors and best management strategies are largely unknown due to a poor understanding of the pathology and
lack of diagnostic biomarkers. However, current research into the pathogenesis of fibrosis in organs now informs the understanding
of arthrofibrosis. The process begins when stress signals stimulate immune cells. The resulting cascade of cytokines and mediators
drives fibroblasts to differentiate into myofibroblasts, which secrete fibrillar collagens and transforming growth factor-β (TGF-β).
Positive feedback networks then dysregulate processes that normally terminate healing processes. We propose two subtypes of
arthrofibrosis occur: active arthrofibrosis and residual arthrofibrosis. In the latter the fibrogenic processes have resolved but the
joint remains stiff. The best therapeutic approach for each subtype may differ significantly. Treatment typically involves surgery,
however, a pharmacological approach to correct dysregulated cell signalling could be more effective. Recent research shows that
myofibroblasts are capable of reversing differentiation, and understanding the mechanisms of pathogenesis and resolution will be
essential for the development of cell-based treatments. Therapies with significant promise are currently available, with more in
development, including those that inhibit TGF-β signalling and epigenetic modifications. This review focuses on pathogenesis of
sterile arthrofibrosis and therapeutic treatments.
Bone Research             (2019) 7:9 ; https://doi.org/10.1038/s41413-019-0047-x
INTRODUCTION
Arthrofibrosis is a fibrotic joint disorder characterised by
excessive collagen production and adhesions that result in
restricted joint motion and pain. It can occur in most joints,1 and
is referred to by a number of names including frozen shoulder,
adhesive capsulitis, joint contracture, stiff knee and stiff elbow.
Sterile arthrofibrosis is typically caused by chronic or repetitive
injury or surgery that leads to a dysregulated immune reaction
and fibrosis in and/or around a joint2 to varying degrees.
The fibrotic scar tissue that forms in the joint is known
as extracellular matrix (ECM), and is primarily composed of
collagen. Although the term ECM includes a wide variety of
biological components we use this established terminology
when discussing fibrotic scar tissue. This forms adhesions within
joint capsules and contracts tendons and bursa around the
joint,3 causing the loss of joint flexion and/or extension. In
addition, scarred bursa may impinge into the joint causing more
inflammation. Together with reduced range of motion (ROM),
pain and varying amounts of swelling are commonly reported
by patients. Arthrofibrosis affects people of all ages, although it
is rare in children.4
Arthrofibrosis frequently causes significant disability; how-
ever, the nature of the disability depends on the joint affected
and disease severity. When arthrofibrosis affects the knee
symptoms become intensified during walking and standing,
and the condition is frequently more debilitating than the
original injury or degenerative condition.5 Even a small loss of
knee extension of 5° creates difficulties in walking while a loss
of flexion creates problems with stair climbing, sitting, getting
in and out of chairs6 and cars and driving. Papers sometimes
state that arthrofibrosis is a “frustrating” or “disappointing”
problem for both surgeon and patient,7–11 however, these
descriptions do not adequately describe the effects that
arthrofibrosis has on patients’ lives. Patients frequently suffer
constant pain, severe limitations on physical activity and
difficulty sleeping, sitting and weight bearing.12 These symp-
toms may lead to the loss of job/career and difficulty socialising
and performing daily living tasks, negatively impacting physical
and emotional well-being.
On a cellular level arthrofibrosis is characterised by upregulated
myofibroblast proliferation with reduced apoptosis, adhesions,
aggressive synthesis of ECM that can fill and contract joint
pouches and tissues and often also heterotrophic ossifica-
tion.1,13,14 Although ECM is necessary for healing and wound
repair, dysregulation of production and degradation leads to
pathologic fibrosis.1,15 While there are relatively few studies into
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the pathogenesis and molecular biology of arthrofibrosis com-
pared to other fibrotic diseases,1 there are common pathogenic
pathways.16–18
This review highlights current progress in understanding
the pathogenesis of sterile arthrofibrosis, focusing on arthrofi-
brosis of the knee to illustrate the condition. The regulation of
inflammation, myofibroblast proliferation and survival and ECM
production involves a highly complex array of mediators, cell
types, receptors and interactions. A detailed explanation of all of
these factors is beyond the scope of this review; therefore, we
present a summary of the important cytokines and mediators
involved in the condition. In addition this review examines
currently available medications and developing pharmacologi-
cal therapies that hold significant promise in the treatment of
arthrofibrosis.
CHARACTERISATION AND CLASSIFICATION OF
ARTHROFIBROSIS
Although arthrofibrosis is often attributed to surgery, it can be
caused by injury alone.19 This may be particularly true for shoulder
arthrofibrosis (frozen shoulder), where the cause is often not
known,20 but which may result from repeated small injuries over
time, or damaged structures that place ongoing stress on the joint.21
The extent of involvement of the joint varies greatly. The formation
of ECM may be localised, for example, cyclops lesions on tendons or
generalised to involve much of the joint6,12 (Fig. 1). In knees the
suprapatellar pouch, anterior interval, intercondylar notch, medial
and lateral gutters, posterior capsule and infrapatellar fat pad (IFP or
Hoffa’s fat pad), may all be affected,6 with symptoms varying
depending on the location and extent of the ECM and adhesions,
but typically involving loss of flexion and/or extension (see above).
When the posterior capsule is affected contracture of ECM often
prevents full extension of the leg, causing abnormal gait.3 ECM
around the IFP causes patella infera (also called patella baja,
Fig. 2). Shortening of the patellar tendon also contributes to this,
Fig. 1 a Side view cross-section showing a healthy knee. b A knee
with generalised arthrofibrosis. Major areas that are affected by
arthrofibrosis are indicated. Black arrow= suprapatellar pouch. In
“b” adhesions have pulled the walls of the pouch together
with extracellular matrix (ECM) contracting the space and prevent-
ing normal movement. Green arrows= posterior capsule. In “b”
scar tissue has contracted the folds of the posterior capsule,
tightening them and affecting movement. The normal gutters at the
side of the joint and the other bursae can also be affected. Blue
arrow= anterior interval and infrapatellar bursa. In “b” inflammation
and scar tissue has contracted the anterior interval and pulled the
patella downwards, resulting in patella infera (baja). The patellar
tendon adheres to the anterior interval and shortens, restricting
movement
a
b
Fig. 2 a Sagittal fast spin echo intermediate-weighted image of a
33-year-old woman with clinical stiffness following anterior cruciate
ligament (ACL) reconstruction, showing scarring of the synovium
around the ACL reconstruction (long arrow) as well as the central
portion of the deep infrapatellar fat pad (short arrow) and the lining
of the suprapatellar recess (oval). b Magnetic resonance imaging of
the knee of a 49-year-old male with clinical stiffness 2 months
following a meniscus operation, showing deep infrapatellar fat pad
scarring (long arrow) and shortening of the patella tendon (short
arrow) with resultant patella infera (abnormally low lying patella)
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leading to patellofemoral pain22,23 and often osteoarthritis (OA) at
a later stage. The IFP may become fibrotic and impinge in the joint
when the knee is flexed, creating further inflammation and
fibrosis, loss of flexion and pain.24 The IFP is a store of immune
cells that secrete inflammatory cytokines under stressful condi-
tions25 (see “Risk assessment”), and can fill with ECM when
adipose cells transform into fibrous tissue.26
The causes of arthrofibrosis are poorly understood,27 and
explanations frequently depend on the training of authors. Shoulder
arthrofibrosis has been recognised as an inflammatory condition for
some time,28 however, orthopaedic surgeons specialising in knees
have traditionally cited physical/mechanical causes such as poor
surgical technique and non-compliance of patients in rehabilitation
(for example,7,9,29,30). Nonetheless, the role that inflammation plays
in arthrofibrosis is increasingly being recognised by the surgical
community.6,12,31 Studies by immunologists and rheumatologists
demonstrate that dysregulation of the immune system and wound
healing processes, including inflammatory chemokines, cytokines
and proteins, leads to fibrosis18 following an insult such as surgery.
Indeed, surgery to treat anterior cruciate ligament (ACL) injury has
been associated with a significantly higher risk of arthrofibrosis than
conservative management.29 Immobilisation is also frequently cited
as a contributing factor.14,19
Understanding arthrofibrosis, its causes, rates of occurrence and
the success or failure of treatments has been complicated because
the condition was poorly defined.32 Definitions have varied widely
and are sometimes subjective, as are measures of treatment
outcomes.33 Recently, an international panel of experts from
multiple medical disciplines developed a consensus definition and
classification of knee arthrofibrosis, which stated “post-operative
fibrosis of the knee was defined as a limited ROM in extension
and/or flexion”, measured by active flexion and extension, which
was not caused by infection of other specific causes.32 Mild,
moderate and severe arthrofibrosis was classified as flexion range
of 90°–100°, 70°–89°, and less than 70°, respectively, and/or a loss
of extension of 5°–10°, 11°–20° and more than 20o, respectively.32
The presence of pain was acknowledged as being an important
aspect of the condition. This consensus definition should assist
arthrofibrosis research and should be widely applied.
The Shelbourne classification34 has been widely used for knee
arthrofibrosis in the past, but was developed from patients with
arthrofibrosis arising from ACL reconstruction. Using these criteria
a diagnosis of arthrofibrosis requires a loss of extension, excluding
many patients with debilitating arthrofibrosis that have pain and a
loss of flexion but not a loss of extension. For example, a recent
case report identified a young woman with arthrofibrosis who had
only minimal loss of ROM, but considerable pain, inflammation
and disability.12 The presence of excessive ECM was confirmed by
arthroscopy.
It is sometimes stated that arthrofibrosis is a rare complication
of surgery29; however, some authors describe the condition as a
common complication of total knee replacement (TKR) and ACL
reconstruction surgeries.8,33,35–37 Estimates of the rates of
arthrofibrosis following ACL reconstruction range from 2% to
35%,22,29 and after TKR between 0.2% and 10%38 with others
reporting rates up to 15% (ref.32 and references within).39 One
large study of TKRs in more than 64 000 patients in the US found
that rates of arthrofibrosis for which revision surgery was
performed was 0.2%.38 However, Abdul et al. reported post-TKR
rates of arthrofibrosis of between 3% and 10%,40 and rates of 4%41
and 12%42 have been reported, with one review paper citing rates
of stiffness from 8% to 60% following a TKR.36
In a study by Werner et al.,5 all surgeries in a national sample of
specific cohorts for non-TKR knee surgeries were investigated.
Rates of arthrofibrosis requiring a manipulation under anaesthesia
(MUA) or arthroscopy within 6 months of the initial surgery were
up to 8%. This study showed that rates of arthrofibrosis requiring
surgical treatment were significantly higher for ACL reconstruction
compared to meniscectomy and microfracture.5 However, even
exploratory arthroscopies are capable of causing arthrofibrosis.12
While some of the confusion about the rates of post-operative
arthrofibrosis are due to the lack of an agreed definition,32 other
factors most likely come into play too. Papers may not reflect the
true rates of arthrofibrosis29 due to reporting bias. Actual rates of
arthrofibrosis following surgery are likely to be higher than the
reported rates, since patients may not be treated surgically.5
Registries of joint replacement outcomes do not include
arthrofibrosis unless the patient undergoes a surgical procedure
to exchange or remove prostheses,32 and the incidence of
untreated arthrofibrosis is unknown.
Arthrofibrosis is a form of fibrosis43 and common pathogenic
pathways occur in fibrosis of organs and tissues.15,17,44,45 However,
specialised cell types in some organs may have organ-specific
influences.43 In fibrosis myofibroblasts are activated and dysregu-
lated as a result of inflammation,46 and inflammatory cytokines are
known to upregulate the factors that induce arthrofibrosis.43
Despite the increasing use of preventative measures after
surgery, it appears that arthrofibrosis rates have remained
relatively constant.29 A lack of an understanding of the role that
inflammation plays in arthrofibrosis can lead to overly aggressive
physical therapy programmes, with papers frequently recom-
mending “aggressive” physical therapy as soon as possible after
surgery.7,42,47,48 However, aggressive exercise can initiate or
worsen arthrofibrosis32,48 because exercise triggers an inflamma-
tory response49 including an increase in inflammatory cytokines,
collagen production and TGF-β,50,51 factors that are dysregulated
in fibrosis (see below). Some patients on international knee forums
report that their symptoms either began or became significantly
worse after they were instructed to “push through the pain”
during rehabilitation, or performed more strenuous exercise.
TWO “TYPES” OF ARTHROFIBROSIS?
Pain and some degree of inflammation are recognised symptoms
of arthrofibrosis,32 yet some papers on knee arthrofibrosis only
discuss “stiffness” as a symptom, for example,8,11,52 and either
specify a painless joint,7 or do not mention pain and inflammation
at all. We suggest that what is termed “arthrofibrosis” may be two
different conditions, (1) an active condition in which ECM
formation and inflammation are continuous processes driven by
positive feedback loops and (2) residual arthrofibrosis, in which
the joint has limited ROM due to existing ECM, but the active
inflammatory and ECM deposition phases have resolved. The
presence of the inflammatory cytokines tumour necrosis factor
alpha (TNF-α) and interleukin-1β (IL-1β) in acute pulmonary
fibrotic tissue, but not in older fibrotic tissue,53 suggests one
way in which active and residual fibrosis may differ, and an
explanation in part for differing pain levels between the two
arthrofibrosis groups, but research is lacking.
Misdiagnoses may complicate the understanding of arthrofi-
brosis. For example, Pujol et al.35 describe two types of patients
with arthrofibrosis, those with swelling and pain in addition to loss
of ROM, and those with primarily a loss of ROM. The first group of
patients is described as having complex regional pain syndrome
(CRPS), a type of neuropathic pain caused by nerve damage, and
the authors recognise that this group of patients should not be
operated on. However, there are no specific diagnostic tests for
CRPS, and no clinical features that identify it.54,55 Consequently,
the diagnosis of CRPS is made in the absence of other
explanations for pain and swelling, and it remains a controversial
diagnosis.54,55
Without publically available blood tests for arthrofibrosis, it
seems likely that many patients that have been diagnosed with
CRPS do in fact have active arthrofibrosis and a dysregulated
inflammatory response. Indeed, a significant majority of patients
diagnosed with CPRS type 1 have muscle weakness or limited
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ROM (ref.55 and references within). It is nonetheless worth
recognising that inflammatory cytokines sensitise the peripheral
and central nervous system leading to persistent pain in the
presence of chronic low-grade inflammation.56
Indeed, under these conditions it is thought that persistent
synthesis of substance P, a known pain sensitiser and activator of
mast cells and fibroblasts, occurs, and creates a positive feedback
loop.14 In support of this, an increased ratio of sensory nerves
(expressing substance P) to sympathetic nerves was found in
tissue from arthrofibrotic knees.57 Also of note is the fact that
chronic low grade inflammation frequently does not have obvious
physical signs or markers in the blood,56 but can nonetheless play
a role in active arthrofibrosis.
More research is needed to understand the difference between
active and residual arthrofibrosis, as the response of patients
within these groups to surgery and exercise may be significantly
different. In support of this, Panni et al.7 report that painful stiff
knees do not respond well to arthroscopic surgery to lyse
adhesions, and Babis et al.27 report that surgery to treat
arthrofibrosis in TKR patients resulted in worse outcomes for pain
in all patients, with some also losing flexion. Surgical lysis of
fibrotic material is the standard treatment for arthrofibrosis,
however, surgery stimulates wound healing processes, including
ECM proliferation, and is associated with increased inflamma-
tion.58 In addition, immune system memory and/or feedback
processes that may be occurring in a patient with active
arthrofibrosis may be further stimulated by surgery. It is known
that re-occurrence is frequent after the removal of ECM in some
conditions.15
Possible parallels with active and residual knee arthrofibrosis
can be found in shoulder arthrofibrosis, in which pain may resolve
with time or remain together with ROM limitations,28 and in other
fibrotic diseases. There are several fibrotic diseases of the lungs,
including simple pneumoconiosis, in which fibrosis begins and
stops, and progressive massive fibrosis, in which extensive fibrosis
progresses until fatal.59 Simple pneumoconiosis can turn into
progressive massive fibrosis if exposure to dust and inflammation
continues. Liver fibrosis is another possible parallel, as it can
sometimes be stopped and even reversed60 using anti-
inflammatory or anti-viral medications, but can turn into active,
progressive fibrosis.61 Active fibrosis results from a switch from an
initial Th1 inflammatory cell response to a Th2 cell response with
prolonged exposure to an inflammatory stimulus. While this
switch helps to control the damage caused by immune cells and
promotes healing, it also activates collagen deposition and
fibrosis.62
GENDERS DIFFERENCES IN RATES OF ARTHROFIBROSIS
Women have been reported to be more likely to develop
arthrofibrosis than men,21,63 with studies citing rates 2.5–2.8 times
higher,29,64 although others have not found a gender differ-
ence.33,38 It has been suggested that the higher rates of
arthrofibrosis in women may be due to psychological differences
between the genders and that women may be less active post-
operatively, may not perform rehabilitation as well as men, may
seek more medical interventions, and have “different” pain
tolerance than men.29 But Hemsley65 found no differences in
pain perception or pain reflex between patients at 6 weeks post-
ACL reconstruction surgery, almost half of whom did not recover
full ROM.
However, it is well established that the genders differ in their
immunological responses, with 80% of autoimmune disease
occurring in women.66 Being female is also a risk factor for
OA,38,67 with more women undergoing TKR than men, despite
women having a greater unmet need for this surgery.68 Recent
research shows that OA is initiated and progressed by inflamma-
tion (see below in Risk factors), and that patients with OA have
high levels of inflammatory cytokines in the knee.58
The gender difference in inflammatory responses is due to both
genes and hormones. Women have stronger innate and adaptive
immune responses than men, leading to increased rates of
inflammatory and autoimmune diseases.66 The corollary is that
women have around half the risk of serious post-surgical septic
infection,69 possibly because oestrogen upregulates pro-
inflammatory cytokines including IL-1 and IL-6.70 Transforming
growth factor β (TGF-β), the primary driver of fibrosis, is also
upregulated and activated by progesterone and oestrogen,71
driving an increase in Treg cells at ovulation.72 Because immune
system dysfunction and acute inflammation cause fibrosis,2 the
higher rates of arthrofibrosis in women is likely due to these
immunological differences between the genders.
RISK FACTORS FOR ARTHROFIBROSIS
There are no established methods for determining the risk of
developing arthrofibrosis following surgery. However, by under-
standing the pathology of the condition, it may be possible to
prevent or successfully treat arthrofibrosis,13,42 and a number of
factors are known to be involved (Table 1). Early onset OA may be
a risk factor/indicator for developing arthrofibrosis after injury or
surgery. OA is associated with inflammation,73–76 and the
inflammatory cytokines IL-6 and TNF-α are upregulated in OA
synovial fluid.67,74 Importantly, in a study by Remst et al. over half
Table 1. The stages of pathogenesis of sterile arthrofibrosis of the knee with corresponding clinical features, risk factors and current managements
Pathogenesis Clinical features Risk factors Current management
Inflammatory response, upregulated TGF-β Pain, redness and swelling Surgery or injury •Elevation and icing
•Corticosteroids
•Aspirin
Proliferation of myofibroblasts and ECM
production
Stiffness and restricted range of motion Surgery or injury
Dysregulation of inflammation and TGF-β
signalling, excessive ECM in and around joint,
adhesions and contractions. Epigenetic
alterations
Persistent pain and restricted ROM, with
typically mild swelling. Further ECM
production and contractions of soft tissues,
abnormal gait
•Previous surgeries
•Mutations causing
excessive TGF-β or
inflammation
•Female gender?
•Early onset OA
•Inflammatory and
autoimmune diseases
•Daily CPM
•Exercise rehabilitation
•Control of inflammation
•MUA
•Surgery to lyse
adhesions and debride
ECM
ECM extracellular matrix, TGF-β transforming growth factor β, ROM range of motion, OA osteoarthritis, CPM continuous passive motion machine, MUA
manipulation under anaesthesia
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of patients with OA were found to have fibrosis of the synovium,43
and other studies have also found an association between OA and
fibrosis.75,76
This link with arthrofibrosis is likely due to over-expression of
TGF-β, a well-known initiator of fibrosis (see below) that is also
implicated in the development of OA when expressed at high
levels in subchondral bone and synovial cells.77 TGF-β levels were
higher in subchondral bone of patients with OA compared to
healthy controls, and appeared to lead to increased blood vessel
formation, bone resorption and stress on articular cartilage.78 In
support of this, high levels of TGF-β induced in rats and mice have
led to OA-like lesions.78,79
This suggests that a pro-inflammatory, pro-fibrosis scene exists
for patients with early onset OA. The high numbers of fibroblasts
in knee synovium can drive inflammation67 and become further
activated following surgery. In addition, patients with OA have a
more pro-inflammatory lipid profile in the IFP than individuals
with healthy joints.25The bursa around the knee, particularly the
IFP, produce and store inflammatory cytokines26,58 and immune
cells, including macrophages, T cells, B cells and mast cells that
can be locally activated by an insult to secrete inflammatory
cytokines, particularly TNF-α and IL-6.25,80 Macrophages have been
detected in the IFP at 20 weeks post-ACL reconstruction surgery,58
and are known to play a key role in all stages arthrofibrosis.81
Injury prior to surgery is also a risk factor for arthrofibrosis. ACL
tears have been demonstrated to increase the levels of IL-1β and
TNF-α in synovial fluid, with levels increasing with the degree of
damage and with time since injury.82 It has been suggested that
higher levels of these cytokines are responsible for the later
development of OA.82 TGF-β is also upregulated in the IFP at
2 weeks post-ACL reconstruction surgery,58 potentially contribut-
ing to the high rates of arthrofibrosis after this type of surgery.
More than two previous surgeries are also a risk factor for post-
operative arthrofibrosis,11 indicating that there is a potentiation or
“memory” of each insult, as demonstrated in other fibrotic
diseases.
In other surgery, such as TKR and reconstructive surgery using
artificial ligaments, the implantation of a prosthesis triggers the
formation of fibrotic tissue as the body attempts to encapsulate
the foreign material.83 Implants such as screws that impinge on
tissues also cause an inflammatory reaction,84 and may promote
arthrofibrosis of TKRs that are not well fitted.
Other factors can also come into play. Childhood adversity such
as neglect or abuse is associated with disease and disability later
in life,85 causing higher Th17 cell numbers, a higher IL-6 response
to stress, and autoimmune and inflammatory diseases.86 Depres-
sion and associated poor rehabilitation compliance are sometimes
cited as causative factors for arthrofibrosis,7 however, it is
interesting to note that depression is strongly associated with
inflammation, and inflammation can cause depression.87,88 There-
fore, it seems likely that the inflammatory processes associated
with active arthrofibrosis cause depression.
Other risk factors include pre-existing inflammatory or auto-
immune diseases, including type II diabetes,20 ankylosing
spondylitis and rheumatoid arthritis.7 One study found that
patients with diabetes mellitus had increased rates of arthrofi-
brosis after a TKR,38 possibly due to a pro-inflammatory
physiology.
Biomarkers to assess the risk of developing post-surgical
arthrofibrosis are urgently needed. In addition to pre-surgery
applications, biomarkers could also be used post-operatively for all
joint surgeries to monitor potential for developing arthrofibrosis,
and following a diagnosis, to monitor the condition and its
resolution. Such biomarkers will be essential for the development
and testing of therapies.89 Ideally tests should be minimally
invasive, for example, serum parameters and imaging, and
applicable before surgery and during treatment to follow
progress.90
GENETIC RISK FACTORS
Some patients may have a genetic predisposition for developing
fibrosis,91 with a twin study finding there was a genetic
component to shoulder arthrofibrosis.92 Because multiple biolo-
gical pathways impact on the pathology of arthrofibrosis, it is
likely that there are many types of mutations that can affect the
risk of developing it, including mutations in the immune system,
TGF-β signalling and genes involved in the synthesis or
degradation of collagen. Skutek et al.93 found a possible link
between some varieties of human leucocyte antigen and the risk
of arthrofibrosis. The human leucocyte antigen complex is
involved in immune system functioning.
People with mutations involving TGF-β production or signalling,
which can result in excessive ECM formation,94 may be at
particular risk of developing arthrofibrosis. One candidate condi-
tion is Aneurysms-OA Syndrome, now included under the name
Loeys–Dietz syndrome, in which upregulation of TGF-β signalling
causes early onset OA.95–97
PATHOGENESIS OF FIBROSIS
There is little research into the cell biology and pathogenesis of
arthrofibrosis. However, a wealth of organ fibrosis research
provides important insights into the processes involved in
arthrofibrosis, and is reviewed here. Fibrosis results from a
complex dysregulation of innate and adaptive immunity that is
involved in most chronic inflammatory diseases,15,45,46 and is a
leading cause of mortality.62 Injury causes oxidative stress and
an inflammatory response, inducing pro-inflammatory cyto-
kines98–100 and TGF-β (Figs. 3 and 4).101 This leads to an increase
in mast cells, macrophages and lymphocytes that promote
fibroblast proliferation and reduced vascularisation.13,62
A lack of apoptosis and autophagy within fibrotic tissues have
also been implicated in a number of fibrotic conditions, and may
contribute to fibrotic tissue formation.13 Reduced autophagy leads
to a build-up of defective mitochondria and oxidative stress.102
Immune cell signalling also stimulates an increase in reactive
oxygen and nitrogen species (RONS)13 and positive feedback
between macrophages and lymphocytes, leading to immune cell
dysregulation.62 However, the severity of fibrosis is often not well
correlated with the degree of inflammation,62 and low-level
inflammation that persists over long periods also causes fibrosis.46
Pro-fibrotic cytokines are thought to cause an imbalance
between ECM production and degradation, leading to excessive
deposition of matrix proteins, which are both collagenous and
noncollagenous.15,45 Collagen type I is the main constituent of
ECM. It has high-tensile strength that prevents normal stretching,
and in fibrosis there is a higher ratio of collagen type I to stretchy
elastin, compared to healthy tissues.103 In addition to altered
composition, fibrotic ECM has extensive cross-linking that makes it
very difficult to degrade.89,104 In particular, levels of hydroxyally-
sine cross-linking is increased, and appears to lead to irreversible
collagen accumulation105 together with other effects on cell
signalling and ECM synthesis.89
The ECM that forms in fibrosis is largely cell-free, and serves as a
conduit for immune cells, fibroblasts, nutrients and endothelial
cells during angiogenesis. In addition to proteins the ground
substance of the ECM is comprised of proteoglycans, and these
bind and inhibit or enhance a range of growth factors, proteases,
protease inhibitors and TGF-β (for review see ref. 103).
The inflammatory cytokines and mediators that trigger fibrosis,
together with the cells that express them (see below), are
essential components of a healthy immune system. Typically,
inflammatory cytokines are downregulated after a period of time,
but the continued presence of inflammatory cytokines and
mediators can cause tissue to become pro-inflammatory and
fibrosis may develop. The presence of one inflammatory cytokine
causes the receptors for other cytokines to be made, sensitising
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cells to respond strongly.106 Repeated trauma and/or long-term
inflammation can trigger epigenetic modifications and activation
of myofibroblasts and matrix-related genes.46,107,108 Chronic
inflammation may also result from a lack of bioactive lipid
mediators (LMs) that causes deficient or non-existent resolution
(see “resolvins”), or LMs that don’t have the required regulatory
effects.109
Almost all types of immune cells are involved in fibrosis110
and the pathways are extremely complex. Consequently,
a detailed discussion is beyond the scope of this review,
ROS, PDGF, TGF-β1, Inflammatory cytokines
Macrophages
Th2 cells,
Lymphocytes,
Mast cells
Fibroblasts
Myofibroblasts
Scar tissue,
Adhesions
Chemokines, NF-κB, TGF-β1, Infammatory cytokines, ROS
PDGF, ROS, TGF-β1, Infammatory cytokines
Mechanical stress
Focal adhesion
Tissue
Tissue
Contraction
Cross linkages
forming
α- SMA stress
fibers
Wound or injury: Hypoxia,Substance P,
Inflammasome activation
Extracellular matrix proteins
Extracellular matrix
Fig. 3 An insult such as surgery or injury causes hypoxia and activates inflammasomes in cells, resulting in the production of reactive oxygen
species (ROS), platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β) and a range of inflammatory cytokines and
mediators. These activate immune cells, causing more inflammation and a cascade of events that stimulates fibroblasts to differentiate into
myofibroblasts, the key mediators of fibrosis. Dysregulation and positive feedback loops (curved yellow arrows) result in persistent
pathological fibrosis. TGF-β plays a central role in the process, stimulating fibroblasts to proliferate and differentiate, and to increase their
extracellular matrix (ECM) production. TGF-β also induces the production of ROS and regulates T cell differentiation and proliferation. Nuclear
factor kB (NF-κB) produced by macrophages is activated by TGF-β, as well as many of the inflammatory cytokines induced by it. PDGF
promotes the migration, proliferation and survival of myofibroblasts and upregulates TGF-β synthesis by fibroblasts. The production of IL-1β
by macrophages further stimulates inflammasomes. Mechanical forces and stress also alter fibroblasts, causing them to differentiate into
myofibroblasts. The fibres of α smooth muscle actin (α-SMA) inside myofibroblasts terminate with adhesion complexes on myofibroblast
surfaces and attach to ECM and other cells, generating contractile forces. Over time the cross-linkages in the ECM and focal adhesions become
more complex and further tissue contractions occur. Myofibroblasts resist apoptosis and are able to maintain themselves by secreting TGF-β
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however, we explore the major cell types and cytokines
involved below.
Myofibroblasts
Myofibroblasts are the key effector cells of fibrosis,46,111 remodel-
ling the ECM, and depositing dense fibrotic collagen.15,44,112,113
Myofibroblasts also form cell-to-cell connections and connections
between cells and ECM, creating contractile units and causing the
contraction of surrounding tissues.103,114–116 In the presence of
TGF-β myofibroblasts produce fibres of α-smooth muscle actin (α-
SMA) together with collagen type 1 (for review see115,117). Over
time the focal adhesions become more complex and further tissue
contractions occur, together with extensive collagen cross-
linking.108
Myofibroblasts are important in wound healing, however, they
are not usually found in healthy tissue.103 They are derived from
fibroblasts115,116 and a range of other cells107,113 that have
differentiated in response to inflammatory cytokines such as
TGF-β, IL-1β and IL-6. However, myofibroblasts also produce TGF-
β, IL-1β, IL-6 and platelet-derived growth factor (PDGF), in addition
to reactive oxygen species (ROS) and a range of paracrine signals
that further activate a fibrotic response (for reveiw see ref. 103).
Thus myofibroblasts resist apoptosis and are able to maintain
themselves by secreting TGF-β15 and inflammatory cytokines,
activating immune cells and further fibrosis. In addition, mechan-
ical forces also alter the biochemical actions of fibroblasts, causing
them to differentiate into myofibroblasts.114
During normal wound healing and resolution of inflammation
some myofibroblasts become apoptotic, while others revert to the
original cell type, however, the processes by which this occurs are
not yet understood.90 In fibrosis epigenetic alterations in
myofibroblasts increase the activity of inflammatory and pro-
fibrotic genes118 (see below in Epigenetic alterations), and appear
to serve as a type of memory of the insult.108 Myofibroblasts that
have reverted back to fibroblasts are more likely to become re-
activated when exposed to further insult.60,90 This has implications
for repeated joint surgeries as fibrosis may resolve naturally
and unnoticed, but the presence of reverted fibroblasts that serve
as a store of pre-fibrotic cells may leave the patient susceptible
to arthrofibrosis after subsequent surgeries, as discussed earlier. It
is not known if the formation of ECM is common following
surgery, only becoming apparent when normal function is
compromised.
INFLAMMATORY CELLS AND CELL STRUCTURES
A number of cell types contribute to the initiation and
maintenance of chronic inflammation and fibrotic diseases,
including macrophages, myofibroblasts and Th2 cells.62 In
addition to these factors, protein complexes within the cytoplasm
of cells called inflammasomes produce inflammatory cytokines,
and which serve as a type of “memory” of insult (see below).
Macrophages
Macrophages react to a diverse range of signals by secreting
cytokines and chemokines, and are found in close association with
myofibroblasts.119 They can be activated by TGF-β and can be
important in fibrosis.16 Classically activated macrophages (M1)
secrete inflammatory cytokines, including TNF-α, IL-1 and IL-6.120
M1 also promote the differentiation of Th17 cells, which are also
pro-inflammatory (see below). However, M2 macrophages secrete
anti-inflammatory cytokines, including IL-10 and IL-13, and are
important in the resolution of inflammation.120
Recent research shows that distinct macrophage populations
may control the initiation, maintenance and resolution of
fibrosis.81 Macrophages are an important source of the pro-
fibrosis mediators TGF-β, IL-1β and PDGF.46 PDGF promotes the
migration, proliferation and survival of myofibroblasts,121,122 and
upregulates TGF-β synthesis by fibroblasts.123 In addition, the
production of IL-1β by macrophages can stimulate inflamma-
somes in the lung.46 Macrophages may be able to regulate ECM
synthesis independently of TGF-β,119,124 however, macrophages
are also involved in the resolution of fibrosis via multiple
mechanisms, including the clearing of excess collagen from
damaged tissues and the secretion of collagenases that degrade
ECM components.81
Mast cells
Mast cells initiate and maintain inflammation.111 They may play an
important part in the development of fibrosis125 and appear to be
able to maintain a pro-fibrotic response, producing and storing
many of the cytokines that promote fibrosis14,111 (see below under
Cytokines), including TNF-α, IL-17 and TGF-β.125,126 Mast cells
numbers are increased in fibrotic organs including the lung,127
heart and kidneys. Trautmann et al.128 demonstrated that mast
cells stimulate fibroblast proliferation after attaching and directly
releasing cytokines into their cytoplasm, suggesting an important
mechanism by which fibrosis is promoted and maintained.
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Fig. 4 Four potential signal transduction pathways and their corresponding receptors associated with arthrofibrosis; including TNF-α,
Interleukins (IL1, IL6, IL17, etc.), TGF-β and chemokines ligand-receptor superfamilies, which lead to activation of NF-κB, Smad, MAPK and
multiple downstream gene transcriptions responsible for matrix production and fibrogenesis
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T cells
The type of T cell response to inflammation controls the
magnitude of fibrosis, with Th2 cells promoting the production
of ECM and fibrosis, while Th1 cells are typically suppressive.62,116
Th17 cells are a subset of T reg cells that differentiate in the
periphery in the presence of IL-1β, IL-6 and TGF-β.129 They secrete
IL-17, a cytokine that is important for the activation and migration
of immune cells, inducing them to secrete inflammatory cytokines
and chemokines.129 Th17 cells are suppressed by the amino acid
limitation response, which also enhances autophagy.102
Inflammasomes
Inflammasomes are intracellular protein complexes that activate
an inflammatory cascade by upregulating the production and
maturation of inflammatory cytokines IL-1β and IL-18.2,120,130
Activated inflammasomes play a central role in fibrosis of organs
including the liver,131,132 lungs133 and kidneys,130 upregulating
α-SMA, connective tissue growth factor and collagen type I131.
Inflammasomes serve as an inflammatory memory, however, it is
not yet clear how they remain active in chronic fibrotic
diseases.2
Inflammasomes are present in immune cells and a wide variety
of cells in tissues, including myofibroblasts and fibroblasts, and are
activated by an array of different signals from wounds and
infection. Sterile activators include nuclear factor kB (NF-κB)134
and stimuli generated by cell death or damage, referred to as
damage-associated molecular patterns (DAMPS), which signal the
inflammasome via cell receptors. These diverse stimuli include
ROS, adenosine triphosphate (ATP), mitochondrial DNA and
proteins released from damaged ECM, such as hyaluronan,
heparin sulphate and biglycan.2,120
Inflammasome activity is also regulated by secreted factors and
by cell-to-cell interactions.2 In addition, some inflammatory
cytokines that are released by dying cells, including TNF-α, IL-1α
and IL-1β can act as DAMPS and activate inflammasomes.2,120
Intracellular proteins such as the chromatin associated protein
high-mobility group box 1 (HMGB1) are also released by necrotic
cells and act as DAMPS. Macrophages activated by TNF-α and TGF-
β can also release HMGB1,2 activating inflammasomes and
creating crosstalk between the production of inflammatory
cytokines and the TGF-β signalling, with potential feedback loops
and implications for fibrosis.
Inflammasomes directly and indirectly activate matrix produc-
tion and fibrogenesis in tissue,98 and activate macrophages via
production of IL-1β.98 It is of interest that IL-1β can stimulate NF-
kB and p38 MAPK pathways and the resulting transcription of
inflammatory cytokines including IL-6,120,135 perhaps leading to
another feedback loop between inflammasome activation, IL-1β
secretion and TGF-β production.
The inflammasome component nucleotide-binding domain and
leucine-rich repeats containing pyrin domain 3 (NLRP3) is well
studied. The NLRP3 inflammasome is a key player in sterile
inflammation, and is associated with a range of auto-inflammatory
and autoimmune diseases.2 Tissue damage and the accumulation
of damaged mitochondria increases mitochondrial ROS produc-
tion, which, along with other signals activates NLRP3 and
stimulates processing of IL-1β pre-cursers into the biologically
active form.2,136,137 NLRP3 also regulates ROS production by
mitochondria.138 The activation of capase-1 by NLRP3 activates IL-
1β and IL-18 precursors,2,137 and also causes the secretion of IL-1α
and fibroblast growth factor 22.
CYTOKINES
Many cytokines have been associated with fibrosis, the most
important being TGF-β. Other cytokines known to have involve-
ment are TNF-α, IL-17, IL-1β and the anti-inflammatory IL-10.139 A
combination of inflammatory cytokines upregulates expression of
TGF-β receptors, and inflammation plays an important role in the
development of fibrosis.140
Transforming growth factor beta
Transforming growth factor beta (TGF-β) plays a central role in
the pathology of arthrofibrosis1 and all fibrotic diseases,141–144
causing activation and proliferation of myofibroblasts, inhibition
of collagen degradation, and an increase in ECM synthesis.144,145
TGF-β is produced by most cells, including inflammatory and
effector cells16,146 and regulates immunity.146 It is secreted in
a latent state, and must be activated by cleavage.94 Four
isoforms are known and are involved in the regulation of cell
proliferation, differentiation, adhesion, apoptosis, migration and
fibrosis.94,101,147 TGF-β1 is the most abundant isoform, and is
thought to be the most important in the pathology of fibrosis.148
Experimental induction of TGF-β causes excessive proliferation
of fibroblasts in the knee joints of rats1 and stimulates the
production of ECM, causing rat knee joints to become
completely encased in fibrous tissue.16 ECM also stores latent
TGF-β,94 which is released and activated by the stress between
cell surfaces and ECM149 that occurs during the contraction of
myofibroblasts.
Production of activated TGF-β is stimulated by oxidative
stress,138 platelet degranulation144 and ROS released after injury
or surgical insult.94 While ROS activates TGF-β and results in
apoptosis,150 TGF-β also induces the production of ROS,101,138,151
thus creating a positive feedback cycle. This cycle may be
exaggerated by another effect of TGF-β, the inhibition of the
expression of antioxidant enzymes, including glutathione.101 The
resulting higher levels of mitochondrial ROS significantly upregu-
lates inflammatory cytokines and the production of inflamma-
somes.138 TGF-β also regulates T cell differentiation and
proliferation and the activation and development of natural killer
cells.72
Following the binding of TGF-β to its receptor complex,
cytoplasmic signal transducer proteins called Smads are phos-
phorylated and promote the transcription of target genes in the
nucleus.138,144 TGF-β also signals via non-Smad pathways includ-
ing the extracellular signal-regulated kinase pathway (for review
see ref. 141). In addition, TGF-β induces epigenetic modifications147
(see Epigenetic alterations below) and upregulates matricellular
proteins, which interact with cell surface receptors and the ECM.1
However, the specific DNA sequences that are upregulated by
TGF-β signalling is dependent on cell-specific DNA-binding co-
factors.94
TGF-β drives a shift from Th-1 cells to pro-inflammatory Th-17
cells72 and upregulates the production of IL-11, a cytokine with a
significant involvement in the development of fibrosis, in
fibroblasts (see below). However, it can have different effects
depending on the type of cells that secreted it, and the presence
of other cytokines. For example, TGF-β secreted by regulatory
T cells in the presence of IL-10 can inhibit inflammation and
fibrosis,62 while TGF-β produced by macrophages is pro-fibrotic.81
Mitogen-activated protein kinases (MAPK) upregulate TGF-β
expression in the presence of inflammatory cytokines,147 and
form another feedback loop.
TGF-β is known to start a cascade of other downstream
regulatory effects including a reduction in ECM degradation via
the downregulation of a family of matrix metalloproteinases
(MMPs),152 which include collagenases. Some MMPs are asso-
ciated with the progression of fibrosis, however, some have a
protective effect.153,154 TGF-β also induces tissue inhibitors of
MMPs (TIMPS) that block ECM degradation and regulate MMP
activity.1,15,81 MMPs play a key role in regulating a number of
processes including ECM remodelling, proliferation, apoptosis and
angiogenesis.155 MMPs are also induced by IL-17A, another
cytokine with a significant involvement in the development of
fibrosis15 (see below).
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Interleukin-1
IL-1β is believed to be an important mediator of fibrosis,98
influencing the migration of cells, adhesion, matrix metalloprotei-
nase production and the expression of immune-modulatory
genes.156 It is a powerful inflammatory cytokine that induces
TGF-β133,145 and PDGF,103 driving the development of fibrosis116
following injury or infection. IL-1β is expressed in fibrotic tissues53
by a range of cell types, but is mainly produced by macro-
phages.157 However, it has been demonstrated that in fibrosis of
the lungs IL-1β acts via TGF-β induction and signalling.145 In auto-
inflammatory diseases IL-1β sets up a feedback loop such that it
stimulates its own production.158
Interleukin-6
IL-6 is a family of cytokines that have been associated with lung
injury and the initiation of lung fibrosis,159 with fewer fibrotic
changes seen in IL-6 deficient mice.160,161 Animal models show
that this cytokine increases the expression of TGF-β receptors and
their signal transduction,162 demonstrating another link between
inflammation and fibrosis. IL-6 is essential for host defence against
bacterial and viral infections, controlling T cell functions and
survival. IL-6 also appears to be involved in the “memory” of
inflammation163 and the development of chronic fibrosis.161
Recently, Schafer et al. demonstrated that IL-11 is strongly pro-
fibrotic, driving the synthesis of the proteins involved in ECM
production, contraction and other processes active in fibrosis.143
Production of IL-11 is upregulated by TGF-β. Neutralising
antibodies to IL-11 and the deletion of IL-11 receptors inhibited
the effects of TGF-β, suggesting new therapeutic targets for
fibrosis.143 IL-11 is expressed by fibroblasts and other cells.164 It is
a member of the IL-6 family of cytokines, and is also implicated in
tumour progression.165
Tumour necrosis factor alpha
TNF-α is thought to be important in the pathogenesis of
fibrosis.46,116,166–168 It is a pleiotropic inflammatory cytokine169
that causes significant upregulation of TGF-β production168,170
and receptor expression140 and may stimulate fibroblast growth
and collagen type I expression.171 TNF-α also causes fibroblast-like
differentiation and inflammation,138 and PGE2 expression.172 TNF-
α and IL-1 upregulate cyclooxygenase 2 (COX-2) synthesis in
response to an insult.158 These cytokines also induce the
expression of intracellular adhesion molecule-1 (ICAM-1),158
expressed in vascular endothelium, macrophages and lympho-
cytes, and associated with the development of fibrosis.59 Roberts
et al.152 reported that TNF-α and IL-1β upregulated MMPs in vitro,
potentially providing some anti-fibrotic effects, however, these
cytokines also have pro-fibrotic effects. TNF-α may also be
involved in the “memory” of insult, as TNF messenger RNA is
able to remain elevated for more than 70 days.173
Interleukin-17
IL-17 upregulates the production of TGF-β174 and inflammatory
cytokines from chondrocytes and synovial fibroblasts,175 and
promotes the survival of fibroblasts.67 IL-17 can directly induce the
production of collagen type 1139 and disrupt ECM homoeosta-
sis,176 while promoting MMP production.176,177 It is secreted by a
number of cells types, primarily T-helper 17 (Th17), NK cells and
mast and myeloid cells.67,164 The feedback loops between IL-17
and IL-6, TNF-α and IL-1 are considered important drivers of
chronic inflammatory diseases,139,175 and suggest a mechanism
for the development of chronic fibrosis. IL-17 acts as a pain
sensitiser,67 induces monocyte migration and activates monocyte-
derived macrophages to produce IL-1, TNF-α and PGE2.178
A number of other chemokines and cytokines including IL-13,
IL-4 and IL-5 are associated with a higher risk of fibrosis, while IL-
10 and IL-12 are protective.62,116,161 There is conflicting evidence
for the role of interferon-γ.161
OTHER PRO AND ANTI-FIBROGENIC MEDIATORS
NF-κB is a family of proteins that occur in the cytoplasm of cells in
an inactive form. NF-κB regulates genes and cells involved in
inflammatory responses,179 including the activation, differentia-
tion and function of inflammatory T cells and inflamma-
somes.120,134 It directly and indirectly promotes Th17
differentiation, and dysregulated production of NF-κB is asso-
ciated with a range of autoimmune and inflammatory diseases.120
NF-κB upregulates the transcription of chemokines and
inflammatory cytokines including TNF-α, IL-1β and IL-6 in a range
of innate immune cells, inducing inflammation.120,157 NF-κB in
macrophages and fibroblasts is activated by TGF-β-activated
kinase 1, as well as many of the inflammatory cytokines induced
by it,120 leading to another feedback loop of inflammation and
fibrosis. However, NF-κB is also necessary for inhibiting NLRP
inflammasome activation in macrophages.134
The 5′-adenosine monophosphate-activated protein kinase
pathway
Adenosine monophosphate-activated protein kinase (AMPK) is a
widely expressed member of the serine/threonine kinase family
that is involved in energy regulation and the regulation of a range
of genes involved in fibrosis.180 AMPK activation appears to
regulate macrophages,181 limits ROS production,182 and is
increasingly recognised as playing an important role in suppres-
sing fibrosis.180,181 In addition, AMPK also appears to inhibit
differentiation and proliferation of myofibroblasts and suppress
collagen production.180 Stimulation of the AMPK pathway can
occur via caloric restriction, exercise or medication.181
Specialised pro-resolving lipid mediators
The discovery of resolvins, protectins, lipoxins and maresins has
revolutionised the understanding of how inflammation is resolved.
We now know that resolution is an active biochemical process
mediated by these specialised pro-resolving LMs (SPMs), which act
as a stop signal for inflammation and a return to homoeostasis.109
Specific SPMs have distinct anti-inflammatory, anti-microbial and
pro-resolving effects.183,184 SPMs are derived from essential fatty
acids, particularly omega 3 polyunsaturated fatty acids (ω-3 PUFA)
found in fish oils and some plants, and are necessary in the human
diet.185 SPMs have synergistic effects on immune function,186
downregulating the production of TNF-α and IL-1β,184 reducing
pain, inhibiting neutrophil migration and protecting against
uncontrolled inflammatory responses.185,187
Oral supplements of ω-3 PUFA result in biologically active levels
of SPMs in serum including the important subtypes RVD1 and
RVD2,188 and in synovial fluid, where SPM levels were negatively
correlated with pain.189 These and other SPMs are able to switch
macrophage phenotypes from pro-inflammatory to pro-resolving
(ref.183 and references within), and reduce the expression of
inflammasomes.184 SPM profiles in patients correlate with out-
comes, with a lack of them linked to delayed resolution of
inflammation.184
Importantly, SPMs were shown to be anti-fibrotic in organs
including the kidney190 and liver.191 PDGF-induced myofibroblast
proliferation is inhibited,190 along with the production of
inflammatory cytokines, and SPMs may represent an important
new treatment for fibrosis.190 Although SPMs have a short half-life
in vivo, more stable synthetic analogues have been developed,192
and may become a useful therapy for a range of inflammatory
diseases and fibrosis.
Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDS) may prolong
chronic inflammation if used for more than 48 h because the
resulting inhibition of COX-2193 causes inhibition of resolvin
production and other SPMs.56,194 COX-2 is an important anti-
fibrotic enzyme.195 The chronic inflammation induced by
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long-term NSAIDS use is known to activate fibrosis of the
kidneys16,196 and lung.195 However, it is not known how NSAIDS
use affects arthrofibrosis, despite it being a commonly prescribed
treatment.197 Importantly, aspirin is an exception as it acetylates
COX-2, favouring the production of lipid mediator precursors over
pro-inflammatory prostanoids.192
Hypoxia
Hypoxia is the lack of sufficient oxygen to carry out normal cellular
processes, and occurs in tissue surrounding wounds.198 Hypoxia is
believed to be important in the development of fibrosis,198,199 via
wide-ranging effects. It promotes SMAD 2 phosphorylation and
expression of α-SMA, collagen type 1, MMP-2 and TIMP-1.200 The
lower pH created by increased levels of lactic acid may be
important in activating TGF-β and myofibroblasts.201 Furthermore,
fibrotic tissue has reduced vascularity, resulting in permanently
hypoxic tissues and another positive feedback cycle where lactic
acid and fibrotic mediators are continuously expressed.198,201
Many of the effects of hypoxia are driven by hypoxia-inducible
factor-1 (HIF-1), a protein that is a key regulator of genes in
hypoxic tissue.202,203 It is upregulated and stabilised in response to
ROS179 and in tissue with low oxygen levels200 and is important in
both normal wound healing and in fibrosis.198 HIF-1 increases
SMAD3 signalling and thereby TGF-β signalling,204 and upregu-
lates connective tissue growth factor198 and genes involved in
ECM deposition.205 Inhibiting HIF-1 inhibits myofibroblast differ-
entiation201 and reduces transcription of collagen type 1.203,206
HIF-1 is known to be upregulated in cardiac fibrosis202 and
contributes to the progression of liver disease to liver fibrosis.207
Reactive oxygen species
TGF-β, IL-1 and TNF-α stimulate ROS production from a range of
cell types including fibroblasts, and TGF-β can also suppress the
production of antioxidant enzymes.208 TGF-β promotes ROS
production209,210 and in a feedback effect, high levels of ROS
stimulates TGF-β production94 and causes more damage, cell
death198 and the release of cell fragments that act as DAMPs,
causing activation of NF-κB and increased expression of inflam-
matory cytokines. ROS can also directly and indirectly activate
MMPs.
Proteases
MMPs and TIMPS have an important role in fibrosis by
controlling matrix degradation.104,117 They are produced by
macrophages and can have pro- or anti-fibrotic properties
depending on the microenvironment and cytokine expres-
sion.116,117 MMP1, MMP8 and MMP13 appear to be important in
the context of fibrosis due to their ability to cleave collagens 1,
11 and 111.104 Mature ECM with extensive cross-linking is
resistant to degradation, and appears to promote the survival of
myofibroblasts and further collagen deposition.117 Fibrotic
tissue also has reduced vascularisation, and cells within fibrotic
tissue express a hypoxia-specific gene and proteins that indicate
oxidative stress (see above).13,101
Substance P
Substance P is an immunomodulatory neuropeptide released by a
variety of cells immediately following injury. Substance P and its
receptor neurokinin-1 increase pain transmission, and their
synthesis is upregulated in response to TNF-α and IL-6.211 In a
positive-feedback loop substance P stimulates mast cells,111,212
upregulates mediators of inflammation, cell proliferation211 and
antiapoptosis,213 and many pro-fibrosis genes.214 Substance P also
increases the expression of collagen type 1 and α-SMA,215
upregulates TNF-α and promotes adhesion of cells.216 A high
ratio of sensory nerves expressing substance P compared to
sympathetic nerves was found in tissue from arthrofibrotic knees,
suggesting a major role for this peptide.57
EPIGENETIC ALTERATIONS
DNA methylation and histone modifications alter access to DNA,
thereby significantly changing the rates of gene transicription.147
These epigenetic changes, together with the upregulation of
micro-RNAs147 and other noncoding RNAs, are significant in many
diseases179,217 including fibrosis.104,108,118,218–220 They typically
occur in response to environment changes including an increase
in ROS,179 resulting in dysregulated cell signalling pathways221
that can affect collagen expression,104 apoptosis, the immune
system and other fibrotic pathways.218,220
Epigenetic modifications are stable and passed on to subse-
quent generations of cells217,222 unless reversed by specific
agents.223 DNA methylation enzymes add methyl groups to
cytosine bases, blocking gene transcription, and TGF-β drives
increased methylation of anti-fibrotic genes and decreased
methylation of fibrotic genes.147 Increased DNA methylation is
associated with fibrosis of the heart,220 lungs195 and other
organs.147 It triggers myofibroblast activation and resistance to
apoptosis,222,223 and can also trigger histone acetylation, strength-
ening pro-fibrotic effects.222
However, the effects of DNA methylation are sometimes
indirect. For example, Evans et al.195 demonstrated that the
hypermethylation of a COX-2 transcriptional regulator in lung
fibrosis resulted in suppressed COX-2 expression and a fibrotic
phenotype. In addition, hypermethylation of micro-RNA promoter
regions can result in the upregulation of genes normally
supressed by micro-RNA, causing fibrosis.223
Demethylation is triggered by translocation enzymes, and these
are downregulated in liver fibrosis, suggesting that an imbalance
between methylation and demethylation enzymes contributes to
fibrosis.219 In a similar fashion, sirtuins are natural enzymes that
remove acetyl groups on histones, providing protection from a
range of diseases including fibrosis.224
Histone modifications include both acetylation and methylation
of nuclear histones that package DNA, with the former promoting
gene transcription218 and the latter typically suppressing it.147,220
TGF-β is known to alter histone modifications, and acetylation of
histones is associated with myofibroblast activation, increased
production of inflammatory cytokines220 and increased SMAD3
transcription.225 Non-histone protein methylation can also alter
the activity of transcription factors and promote TGF-β signalling
by decreasing Smad7 protein stability.226 Smad7 is an inhibitor of
TGF-β expression.
TGF-β also upregulates a wide range of pro-fibrotic micro-RNAs
and long noncoding RNAs, and downregulates anti-fibrotic micro-
RNAs.147 In liver disease long noncoding RNAs and other
noncoding RNAs can promote or reverse fibrosis via a variety of
mechanisms, including upregulation of CTGF227 and TGF-β
signalling.228
Epigenetic alterations are likely to be significant factors in
persistent active arthrofibrosis, as has recently been shown for
lung fibrosis,195 other fibrotic diseases108,147 and cardiorespiratory
abnormalities from hypoxia-induced DNA methylation and
persistent increases in ROS.229
HISTOPATHOLOGY
Histochemical and immunohistochemical studies have signifi-
cantly advanced the understanding of the pathogenesis of
arthrofibrosis, and fibrosis in general, demonstrating alterations
in tissue composition and structure and cell activity. Commonly
used histological stains are easily applied and readily visualise
fibrotic tissue and ECM,218 permitting patient diagnosis and
visualisation of treatment efficacy in animal models. Although the
results from arthrofibrosis studies have been variable,19 possibly
due to differences in the type of biopsy tissue and the location
and extent of fibrosis of donor patients, these studies have
nonetheless provided important information.
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Table 2. List of existing and potential new therapies for treating arthrofibrosis, with a summary of the associated benefits and risks
Therapies Benefits/risks
Dietary approaches
Omega 3 fatty acids in fish or supplements Necessary for the production of SPMs vital for resolution of inflammation. Thins the blood, but
typically no risks are associated within recommended daily limits.
Capsaicin (in peppers) and sulphoraphane (in
cruciferous vegetables)
May reverse differentiation of myofibroblasts, sulphoraphane may prevent fibroblast
differentiation. No risks are associated within recommended daily limits.
Resistant fibre Gut bacteria produce short-chain fatty acids which counter inflammation. No risks are
associated within recommended daily limits.
Low-sugar intake Reduces inflammation. Typically no associated risks.
Soy products Contains anti-inflammatory compounds. Reduced levels of TGF-β and lung fibrosis in rats.
Benefits not established for treating fibrosis. Typically no risks are associated within
recommended daily limits.
Potassium May help prevent fibrosis, negative correlation between high levels of serum K+ and liver
fibrosis. Typically no risks are associated within recommended daily limits.
Intermittent fasting Protective against fibrosis of organs, suppresses inflammation, IL-1, IL-6 and TNF-α and
inflammasomes. Typically no risks are associated. May be difficult to follow.
Pharmaceuticals
Oral and injected corticosteroids Downregulates inflammation and possibly TGF-β. Increased risk of infections, suppressed
adrenal gland hormone production, can cause high-blood pressure and liver damage etc if
long-term.
TGF-β antibodies? Several TGF-β neutralising antibodies and receptor blocking antibodies are in clinical trials. May
prove to be effective therapies for arthrofibrosis.
IL-1 antibodies and IL-1 receptor antagonists Have been successfully used to prevent post-operative arthrofibrosis in small studies. Shown
effective at reducing lung fibrosis in animals (Gasse et al. 2007). Efficacy in the treatment of
existing arthrofibrosis not known.
Halofuginone? Inhibits Smad3 signalling by TGF-β. Suppresses collagen type I, fibroblasts and Th17 cells.
Causes GI bleeding, enteric coated capsules recommended. Benefits and risks not established
for treating fibrosis.
Low dose aspirin? Induces production of SMPs. Can cause GI symptoms in some, enteric coated capsules
recommended. Blood thinner.
TNF-α antibodies? Reduces pain, inflammation, fibrosis and serum TGF-β in animals. Increased risk of infections.
Benefits and risks not established for treating fibrosis.
Pirfenidone Therapy for lung fibrosis, anti-fibrotic and anti-inflammatory, downregulates fibroblasts,
collagen, alpha smooth muscle cell actin. Diarrhoea, photosensitivity, GI symptoms and liver
toxicity in some.
Nintedanib Therapy for lung fibrosis, anti-fibrotic, downregulates collagen. Diarrhoea, GI symptoms and
liver toxicity in some.
Ketotifen? Used to treat asthma, modifies mast cell activity. Results of small trial for elbow arthrofibrosis
shows no effect.
Metformin? Used to treat type II diabetes. Reduces TGF-β production, interferes with TGF-β signalling,
reduces collagen deposition and proliferation of fibroblasts. Reduces fibrosis of organs.
Collagenase May damage articular cartilage, ligaments and tendons, but trials show no negative effect on
these structures. Repeated injections needed, increases ROM in shoulder arthrofibrosis. More
trials are needed.
Substance P antagonists? Used to alleviate nausea. In animal studies downregulates pro-fibrotic genes in joints and
reduces fibrosis and inflammation of the colon.
Interferon β therapy? Downregulates NLRP3 inflammasomes. Benefits and risks not established for treating fibrosis.
Epigenetic drugs? May reverse myofibroblast differentiation and DNA and histone modifications that cause
persistent fibrosis. Benefits and risks not established for treating fibrosis.
Surgical approaches
Arthroscopic lysis and debridement of ECM Removal of adhesions and ECM can increase long-term ROM. Risk of adverse outcomes from
the inflammatory response and worsening fibrosis. Infection, blood clots. No method to
determine how individual patients will respond.
Manipulation under anaesthesia Disruption of adhesions can increase long-term ROM. Risk of adverse outcomes from the
inflammatory response and worse fibrosis. Risks include heterotrophic ossification, bone
fracture, damage to prosthesis, ligament rupture and blood clots.
Open surgery Removal of adhesions and ECM can increase long-term ROM. Risk of adverse outcomes from
the inflammatory response and worse fibrosis. No method to determine how individual
patients will respond.
Physical therapies
Bracing May be needed for healing. Risk of adhesions forming due to lack of movement.
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Early arthrofibrosis research found increased collagen accumula-
tion in the IFP,230,231 with later studies reporting high numbers of
myofibroblasts positive for the presence of α-SMA232–234 and a
proliferation of fibrotic connective tissue.234 Later, Freeman et al.13
found that fibrotic tissue from the knees of arthrofibrosis patients
contained heterotrophic ossification, limited vascularity and
increased numbers of mast cells expressing fibroblast growth factor.
The number of myofibroblasts in tissue from arthrofibrotic knees
can be ten times higher than in healthy subjects.233 Ruppert et al.234
observed co-localisation of β-catenin and the tight junction protein
ZO-1 in myofibroblasts which may cause increased adhesions
and mechanical loading of cells. This finding can be applied to
distinguish arthrofibrosis from other conditions when tissue samples
are available, with a threshold of 20 myofibroblasts expressing
β-catenin per high powered field of view.234
Other histopathology studies suggest additional pathways
involved in the pathogenesis of arthrofibrosis. Faust et al.232
found increased expression of xylosyltransferase-I mRNA in the
synovial membrane of arthrofibrotic knees treated with TGF-β1,
along with increased α-SMA and collagen. Xylosyltransferases
catalyse the production of proteoglycans associated with fibrosis,
and are involved in tissue remodelling and myofibroblast
proliferation.232
Koeck et al.57 reported an increased ratio of sensory nerves to
sympathetic nerves in tissue from the anterior of arthrofibrotic
knees compared to OA knees. Antibodies to substance P were
used to indicate the presence of sensory nerves, suggesting that
hyperinnervation and high levels of substance P may be
significant contributors to active arthrofibrosis.57
CURRENT TREATMENTS AND NEW THERAPEUTIC OUTLOOKS
Non-pharmacological treatments
Arthrofibrosis research has often focused on treatments that
address the structural pathology of the condition. These
treatments include surgical interventions, such as arthroscopic
lysis and debridement of ECM, open surgery to remove ECM and
release of tendons and ligaments, and MUA.35 Other treatments
include bracing, corticosteroids and physical therapy3,33 (Table 2).
Continuous passive motion. Post-operative use of continuous
passive motion (CPM) is sometimes prescribed to increase
ROM,52,235 but remains controversial, most likely due to the
associated expense and inconvenience.236,237 This results in many
patients not having access to regular CPM.235
Ferretti et al.238 used antibody-induced arthritis in rabbits to
show that CPM lowers levels of inflammatory IL-1β, increases anti-
inflammatory IL-10 and decreases MMP-1 compared to immobi-
lisation. This suggests that the mechanical forces created by CPM
reduce inflammation and pain, and may reduce damage to
cartilage. In addition to potentially increasing ROM, CPM may
further assist post-operative patients by lowering the risk of
arthrofibrosis via these effects, particularly in patients that are not
fully mobile.
Unfortunately, the efficacy of CPM is difficult to determine as
trials differ in their duration, timing and length of CPM treatment.
The number of participants in CPM trials is particularly important
because only a small proportion of patients develop post-
operative arthrofibrosis, and it is only in these patients that a
significant gain in ROM would be anticipated. A 2014 Cochrane
Review that analysed 24 randomised controlled trials of CPM
following TKR over 1–17 days found that CPM use may slightly
increase ROM and quality of life, although these were not clinically
relevant, and low-quality evidence to indicate that CPM reduces
the risk of MUA by 4%.236
This review did not exclude trials based on the quality of the
research, and only ten studies blinded assessors to CPM use.
Increased ROM is the primary reason for CPM treatment, and of
the ten trials that reported short term (0–6 weeks) effects on ROM,
only five used a blinded assessor.236 Even fewer studies used a
blinded assessor for the reported medium term (6 weeks to
6 months) and long-term (over 6 months) ROM. The lack of well
controlled studies makes it difficult to draw conclusions.
In addition, Chaudry et al.237 observed that the 2014 Cochrane
Review results may not apply to patients with “unique considera-
tions”, particularly those that have undergone an MUA and for
whom there is a higher than usual risk of adhesions. It is also likely
that for patients that develop active arthrofibrosis, more than 1 or
2 weeks of frequent CPM are required to counter the continuing
formation of ECM and adhesions. Quality research into the efficacy
of CPM for patients with arthrofibrosis, rather than the general
orthopaedic patient community, is urgently needed.
Surgery and MUA. Arthroscopic lysis of ECM is the most
commonly performed treatment for arthrofibrosis,33,35 and MUAs
are also frequently performed either on their own, or during
arthroscopic surgery. These treatments can be successful, perhaps
not only because of the obvious benefit of removing the physical
restriction to ROM. The release of stress created by the lysis of ECM
can potentially interrupt the feedback loop between myofibro-
blast activation due to mechanical loading and resulting contrac-
tion, in the process encouraging apoptosis of myofibroblasts.113 In
addition, the removal of ECM during surgery removes bound pro-
fibrotic mediators, including TGF-β.108
Nonetheless, the benefits of surgical lysis and MUA should be
tempered by an understanding of the problems associated with
these procedures. Both treatments damage tissues, and tissue
injury stimulates an inflammatory response239 that may cause
Table 2. continued
Therapies Benefits/risks
Exercise, physical rehabilitation therapy Increases strength and ROM. Intensity should be adapted according to resulting inflammation
in individuals. Risk of increasing inflammation and fibrosis when limits are exceeded.
Continuous passive motion Remains controversial. May help to avoid MUA, likely more beneficial for patients with
arthrofibrosis than for those without. Must be well controlled to prevent damage to tendons
and ligaments from forced over-bending.
Other
Mesenchymal stem cells? Modulate the immune system, inhibit the production of inflammatory cytokines. Age and origin
may affect the outcome. May differentiate into fibroblasts. Can encourage tumours. Benefits
and risks not well established for treating fibrosis.
For other potential therapies, including those that inhibit TGF-β signalling, see main text. Patients should always receive medical advice before adopting new
treatments or diets and before altering treatment as this may alter current treatments or comorbidities. Some of these approaches are not well established for
treating fibrosis, but are known to reduce inflammation. SPMs special pro-resolving lipid mediators, RDI recommended daily intake, ROM range of motion,
? a pharmaceutical therapy that is currently used to other conditions, which has potential for treating arthrofibrosis
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further fibrogenesis. One study found that patients with elbow
injuries had significantly less ROM if they were treated surgically
instead of non-operatively at 12 weeks.240 Some authors state that
MUAs should not be performed due to the risk of fractures,
rupture of tendons and cartage damage,35 while others warn that
delayed MUA or manipulation that is too aggressive can lead to
these complications as well as ossification of the medial collateral
ligament and quadriceps.6
Daluga et al.42 found that MUAs significantly increased
heterotrophic ossification in an MUA group compared to a control
group based on radiographic observations. This is probably due to
tearing of tissues during the process and bleeding. One review
found that MUAs had caused hemarthroses, wound dehiscence,
subdural haematoma, bone fracture and two fatal pulmonary
emboli, but reported that most studies did not include enough
patients to show up these risk factors.36
It is difficult to determine how successful surgery is for treating
arthrofibrosis.6 Patients differ widely in the severity of symptoms,
degree of inflammation and extent of fibrosis within and around
the joint, and surgical treatments also vary greatly in extent.
Measures of outcomes and classification of patients also differ,6
affecting reporting.
In addition, studies of surgical procedures to treat arthrofibrosis
are often poor quality.36 They frequently have small sample sizes,
sampling bias and reporting bias,5 and are typically not
comparative33 or controlled, complicating the interpretation of
these procedures.36 The reported high rates of success of surgeries
to treat arthrofibrosis and lack of adverse outcomes do not
correlate well with outcomes reported by patients on patient
websites such as KNEEguru241 and indeed it is understood that
published results of knee surgery including TKRs by specialised
surgical centres may be misleading and overly optimistic.68,242
It is known that surgery sometimes worsens symptoms of
arthrofibrosis,23 but these cases may not be reported. Some
patients are removed from studies of surgical outcomes after a
diagnosis of “complex regional pain syndrome”, a condition with
no established diagnostic criteria (see above). Regardless of
diagnosis, these patients should be included when reporting the
results of surgery, both initial surgery to treat an injury, and
surgery to treat arthrofibrosis. Not doing so is misleading and
makes interpretation of results difficult.
Studies often do not specify how ROM is evaluated, and
changes in ROM are sometimes reported as relative measures.33
Additionally, it is often not reported how severe ROM limitations
are before treatment.33 ROM results are often averaged, obscuring
any patterns that may exist in treatment outcomes. For example,
patients with more severe ROM limitations may not benefit as
much as those with relatively good ROM before treatment, but
this type of outcome typically can not be determined from the
published data.
A recent review of the literature on treatments for arthrofibrosis
included 647 patients in 25 studies, however, only 241 patients
(37%) had their ROM established using a goniometer.33 More than
half of patients were successfully treated without surgical
intervention, and of those that had arthroscopic lysis of ECM 6%
required more than one procedure for ROM deficits.33 Of the
25 studies examined in this review only 6 reported statistically
significant improvement in ROM following treatment.
Everyone is affected by bias, and although well-intentioned,
surgeons have a vested interest in reporting positive outcomes
from their treatments. It is, therefore, important that studies are
well designed to control for bias.243 Unfortunately, double blind
trails are difficult where surgery is involved, but sham surgeries
have been successfully performed to demonstrate the lack of
effectiveness of chondroplasty compared to placebo for the
treatment of OA.244,245 Chondroplasty is débridement (shaving the
cartilage), typically with lavage (wash-out) of the joint, and
remains the most widely performed knee surgery for arthritis,
despite randomised trials showing no difference in pain or
functional status over non-surgical controls.243,246
An additional complicating factor is a history of multiple injuries
or surgeries to a particular joint, which appears to increase the risk
of a patient developing post-operative arthrofibrosis. Unfortu-
nately, the effect of previous surgeries on the outcome of surgery
or MUA is seldom mentioned in published studies, and is rarely
the main focus of a study.6,11 However, Ipach et al. (2011) showed
significantly worse outcomes from an MUA for patients that had
previously undergone one or two surgical procedures. Sachs et al.
stated that 18% of patients that had multiple surgeries developed
arthrofibrosis, compared with 5% that had one surgery to repair
an ACL.22
In a review of patients undergoing treatment for arthrofibrosis,
Werner et al.5 showed that each additional procedure performed
during the surgery incrementally increased the rates of arthrofi-
brosis. While complications from surgical treatment of arthrofi-
brosis are often not reported, or are poorly reported,36 some
authors suggest that the return of arthrofibrosis is common
following these procedures.32
For example, a young female patient with minimal loss of ROM
but considerable pain underwent three surgeries to lyse ECM and
adhesions, however, each surgery appeared to worsen the pain
and inflammation despite a focus on decreasing inflammation.
There were serious complications after the final surgery including
poor healing, neuropathy, quadriceps atrophy, unresponsive
swelling and excessive pain.12 This patient demonstrates the
important point that systems to diagnose and grade the severity
of arthrofibrosis based on ROM will fail to include some patients
that have severe pain and disability from the condition, but only
limited ROM loss. In this case the patient’s flexion only dropped
below 100° for a 1-week period after the third operation, and her
extension was never worse than 0°.
Nonetheless, surgical removal of ECM from the joint may assist
when the inflammatory response that arises from surgery can be
controlled. ECM promotes survival of myofibroblasts and the
deposition of collagen, and once mature is resistant to degrada-
tion.117 This likely explains why some patients that have surgical
lysis and removal of ECM recover. However, patients with minimal
loss of flexion may be best treated with conservative, non-surgical
interventions given a basal risk of complications of around 4.7%
from arthroscopic knee surgery,247 together with the risk of
recurring arthrofibrosis. The overall risk of surgical complications
such as infection is significantly higher for young men than for
women over 40.247
The inflammatory reaction to surgery and foreign material in
implants could potentially be controlled by the use of implant
coatings that interfere with macrophages.84 In a similar manner,
anti-fibrotic drugs could also be developed as coatings for
implants to prevent post-operative arthrofibrosis.83 Halofuginone
is a promising anti-fibrotic candidate (see below) and implant
coatings of halofuginone have been shown to reduce the fibrosis
in rats.248
Alternatively, slow release capsules of anti-fibrotic drugs or
scaffolds containing drugs could be introduced at the time of
surgery, or after arthrofibrosis develops. Arsoy et al.249 successfully
used surgically implanted intra-articular hydrogel scaffolds con-
taining rosiglitazone in a rabbit model of arthrofibrosis to reduce
loss of ROM from trauma. This approach could be used to prevent
the return of arthrofibrosis at the time of surgery to lyse adhesions
and remove ECM. Some of these approaches may increase the risk
of infection, and additional anti-microbial coatings or implants
containing antibiotics84 could be applied.
PHARMACOLOGICAL TREATMENTS
Because fibrosis is caused by an imbalance in cytokine production
activated by high levels of TNF-α, IL-1,139 TGF-β and other
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mediators an effective therapeutic approach may involve regulat-
ing cytokines and mediators to favour resolution. However,
despite the understanding of the pathogenesis of fibrosis, there
are no effective therapies to halt fibrosis, and none to cure it.16,107
This situation may soon change, with a range of pharmacological
therapies in clinical trials for the treatment of fibrosis of organs.17
The large number of potential therapeutic targets116 may have
complicated and slowed progress. A review of the mechanisms
and experimental approaches to kidney fibrosis in diabetic
patients found 17 mechanisms and 80 experimental approaches
to inhibit ECM formation.250 It is possible that multiple pathways
need to be targeted together for the most effective outcome,17,251
particularly when fibrosis is well established. Nonetheless, it is also
possible that targeting one or two key mediators early in the
process may halt the dysregulation that leads to permanent active
fibrosis, and targeting epigenetic modifications could potentially
turn active arthrofibrosis into residual arthrofibrosis. Arthrofibrosis
may be a useful candidate for testing new therapies since it can be
identified early after surgery, unlike fibrosis of organs that are
typically detected late in the disease process.
Although fibrosis has been considered an irreversible condition,
it is significant that some studies show that fibrosis can be
resolved and sometimes reversed at least partially in animal
models and humans, demonstrating that the synthesis and
degradation of ECM is dynamic and can proceed in both
directions.45,107,108,117,252 For example, in the knee, linear scarring
sometimes occurs along the arthroscopic portal paths. This peaks
at 6 months, but after a year is no longer present in half of
patients,253 suggesting that fibrosis is a frequent reaction to
surgery that often resolves without treatment.
Treatment of lung fibrosis has improved recently with the
introduction of pirfenidone and nintedanib.251 Pirfenidone down-
regulates inflammatory cytokines including TNF-α, IL-1β and IL-6
in addition to its anti-fibrotic effects of blocking TGF-β stimulated
collagen production, production of PDGF, α-SMA and fibroblast
proliferation.251 These treatments may be beneficial for treating
arthrofibrosis either on their own, or in combination with other
therapies, since therapies for treating organ fibrosis are likely to be
effective for the treatment and prevention of arthrofibrosis.
The role of hypoxia in the development of arthrofibrosis
requires research. Future treatments for fibrosis may target
hypoxia-inducible factor-1 or its downstream signalling202 to
prevent areas of reduced vascularity and positive feedback with
TGF-β production and myofibroblast activation. Another target for
early intervention is substance P. Recent research has found that
knockout of the receptor for substance P attenuates liver fibrosis
in animal models,213,254 while other animal studies found that a
receptor antagonist for substance P downregulated some pro-
fibrotic genes in joints214 and reduced fibrosis and inflammation
of the colon.255 Substance P antagonists are routinely used to
alleviate nausea.214
Anti-inflammatories
Although anti-inflammatory medications do not halt fibrosis of
organs,107 they are nonetheless the only currently prescribed
medications for treating arthrofibrosis. Aspirin has been shown to
inhibit production of NF-κB via the IKK receptors,120 and
importantly, aspirin triggers the production of more stable and
potent SPMs.256–258 In animal models of liver fibrosis aspirin
reduced levels of pro-fibrogenic mediators and the progression of
fibrosis.259 As mentioned previously, NSAIDS other than aspirin
have been shown to disrupt class switching of COX-2, preventing
the production of SPMs and inducing long-term
inflammation.56,256,257
Corticosteroids, particularly glucocorticoids, are frequently
prescribed to patients with arthrofibrosis in oral or injected form,
and reduce symptoms. Glucocorticoids such as glucocorticoid
dexamethasone and annexin peptides and their derivatives
downregulated inflammation in lung fibrosis and reduced the
infiltration of neutrophils and monocytes.260 The peptide Ac2-26,
an annexin derivative, inhibited collagen deposition as well as
TGF-β and TNF-α in mouse models.260 Glucocorticoids also inhibit
the DNA-binding of NF-κB.120 Prednisolone reduces the expres-
sion of adhesion molecules, limits tissue damage and may
downregulate TGF-β in liver fibrosis, particularly when used
together with azathioprine.61
IFN β therapy appears to be an effective treatment to
downregulate NLRP3 inflammasomes.261 Several other treatments
that target the NLRP3 inflammasome, some of which are currently
available, are reviewed by Shao et al.,261 and may be a useful anti-
inflammatories for treating or preventing arthrofibrosis in high-risk
patients.
Another medication that is currently available may also assist in
treating arthrofibrosis. Ketotifen is an antihistamine used to treat
asthma, and modifies mast cell activity. Monument et al.262 found
that ketotifen treatment reduced arthrofibrosis in rabbits by
decreasing the numbers of mast cells and myofibroblasts.
However, a recent clinical trial to evaluate the use of ketotifen
to reduce elbow contracture after injury demonstrated no
significant increase in ROM at 12 weeks in a group treated with
oral ketotifen compared to the control group.240 This result is
difficult to interpret due the low numbers of patients, with only
34% of the ketotifen treatment group having surgery. The number
of patients that developed arthrofibrosis was not reported. More
trials will be necessary to determine if ketotifen can prevent
arthrofibrosis, and evidence suggests that it should be adminis-
tered soon after surgery or injury for the most effective
outcome.14
Modifiers of TGF-β signalling
Although TGF-β is the primary inducer of fibrosis,16 blocking its
production is complicated by the many essential biological roles it
plays.94,144 Some studies therefore aim to modify downstream
signalling to minimise side-effects. However, there are many
different aspects of TGF-β production, activation and signalling
that can be targeted therapeutically, with antibodies, antisense
oligonucleotides, ligand competitive peptides and inhibitors in
clinical trials.94
Some medications already in use for other conditions may have
therapeutic potential for arthrofibrosis. Metformin has been used
extensively to treat type II diabetes and has risen to prominence
after it was found to reduce death from all causes.263 Metformin
appears to reduce TGF-β production159,264–266 and interferes with
TGF-β signalling,264–266 reducing fibrosis of the kidney,265,267
lung,159,264 heart263,266 and liver.268,269 Zheng et al.270 found that
metformin reduced fibrosis of tendons in rats, which had reduced
adhesions and α-SMA expression in tendons compared to
controls. Furthermore, metformin did not inhibit healing. In vitro
analyses in the same study indicated that metformin decreased
levels of Smad 2/3 phosphorylation and extracellular signal-
regulated kinase 1/2, suggesting that metformin targets canonical
and non-canonical pathways in TGF-β signalling.
In vitro and animal studies show that metformin reduces
collagen deposition and proliferation of fibroblasts after initiation
of fibrosis compared to non-treated controls,159,264,270 with some
of these studies also showing reduced levels of α-SMA expression.
Metformin reduced levels of inflammatory cytokines, including IL-
6, IL-17 and IL-18263 as well as TNF-α in animal models of lung
fibrosis.264 Qin et al.271 reported that metformin decreased levels
of messenger RNA for inflammatory cytokines in vitro and reduced
alkaline phosphatase activity, a marker of osteogenesis, in human
ligament fibroblasts.
Metformin has also been shown to suppress expression of
hypoxia-inducible factor-1 and to activate the adiponectin-5′-
AMP-activated protein kinase (AMPK) pathway.272 Together these
results indicate that metformin may have significant therapeutic
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potential for the treatment of arthrofibrosis, and the well-known
safety profile of this medication makes it particularly attractive.
Halofuginone also suppresses TGF-β, but does not have the
well-known safety profile of metformin. Halofuginone directly
inhibits Smad3 signalling by TGF-β.15,114 Smad3 upregulates the
production of pro-fibrotic proteins and miRNAs,147 and is
considered essential in the fibrotic process.144 Halofuginone
reduces collagen type I, suppresses myofibroblast proliferation
and has been shown to resolve and reverse established fibrosis in
animals models.15,273 The reduction in collagen type I synthesis
appears to be the result of inhibited gene expression15,274 and
only occurs in soft tissues, not in bone.15
In addition, halofuginone inhibits the development of Th17
cells,44 decreasing Th17 cell numbers and inflammatory cytokines
via AMP-activated protein kinase-mediated NF-κB p65 inactiva-
tion.275 Halofuginone has undergone clinical trials to treat
Duchenne muscular dystrophy and several forms of cancer using
an oral encapsulated form to prevent gastric bleeding. Injections
of halofuginone are also effective in animal models, and could
potentially be used post-surgically in the joints of patients at risk
of developing arthrofibrosis. The ability of halofuginone to supress
the production of TGF-β by fibroblasts15 may be particularly
important for treating active arthrofibrosis, and its ability to trigger
the dissolution of collagen and decrease established fibrotic
conditions15 could potentially assist patients with well-established
arthrofibrosis.
Another modifier of the expression of activated TGF-β was
recently demonstrated to have some efficacy in rat models of
kidney fibrosis. MK-0429 is thought to downregulate some or all of
the TGF-β cell receptors necessary for activation of TGF-β, leading
to reduced collagen type 1 production.276 This compound is taken
orally, and was first developed to treat osteoporosis.
Other therapies that inhibit TGF-β signalling are discussed in
Lichtman et al.,148 Lee et al.277 and Xu et al.94
Epigenetic regulators
Drugs that target epigenetic modifications hold significant
promise for treating and even reversing fibrotic conditions due
to the ability to alter gene transcription in many pathways
simultaneously.278 This potential has recently been recognised,
and epigenetic drugs are beginning to be tested for efficacy in a
range of fibrotic diseases. For example, Evans et al.195 showed that
inhibition of DNA methylation enzymes could reverse the down-
regulation of COX-2 expression in lung fibroblasts and de-activate
them.
Myofibroblast differentiation is a particularly attractive tar-
get,46 and epigenetic reprogramming and de-activation of
myofibroblasts could control dysregulated TGF-β signalling,
inflammatory cytokine production and ECM synthesis and cross-
linking.219 However, further research is needed to clarify the
functions of specific inhibitors and promoters, as they can affect
many cell types and can have off-target effects including the
deacetylation of proteins.220,279 Zeybel et al.278 demonstrated
that myofibroblasts in liver fibrosis could be targeted using
liposomes coated with myofibroblast-specific antibodies to
deliver epigenetic drugs, potentially side-stepping potential
issues with off-target effects.
Histone deacetylase inhibitors have been effective in treating
liver and kidney fibrosis in rodents,218 and Schuetze et al.279
demonstrated that diverse histone deacetylase inhibitors were able
to suppress proliferation of cardiac fibroblasts in vitro. In addition,
the knockdown of a noncoding RNA was shown to reduce liver
fibrosis in mice by reducing TGF-β signalling228 and sirtuins were
shown to downregulate inflammatory cytokines and M1 macro-
phages via deacetylation of a NF-κB subunit,220 refs therein.
Zhang et al.224 demonstrated that abnormally high levels of sirtuin
6 suppressed myofibroblast differentiation in human cells in vitro
by inhibiting TGF-β and NF-κB signalling pathways.
Currently prescribed medications with a known safety profile
can be readily trialled as epigenetic regulators. Valproic acid is
currently prescribed for migraines and other conditions, and is a
histone deacetylase inhibitor.218 Li et al.227 showed that valproic
acid could reverse human liver myofibroblast activation in vitro,
with the possible involvement of noncoding RNAs. Long-term
valproic acid treatment also reduced ROS, TNF-α, IL-6, IL-1β and
NF-κB activity and expression in diseased rat hearts.280 Other
epigenetic compounds are reviewed by Nebbioso et al.217 and van
Beneden et al.218
Dietary phytochemicals may also be useful, with many,
including polyphenols, curcumin, quercetin, soy isoflavones,
lycopene and resveratrol shown to reverse epigenetic modifica-
tions, often acting on more than one class of epigenetic
modification.281
BIOLOGICS
TGF-β antibodies
A number of TGF-β neutralising antibodies have been developed
and tested in a range of conditions including OA. Neutralisation of
TGF-β may be a powerful therapy that interrupts the positive-
feedback loop between this cytokine and myofibroblasts,94 and
could potentially lead to the resolution of active arthrofibrosis.
Several TGF-β neutralising antibodies as well as receptor blocking
antibodies have been developed and have passed early clinical
trials for fibrotic diseases and cancer.94
IL-1 antibodies and IL receptor antagonists
IL-1 antibodies such as Rilonacept bind to and inactivate IL-1. In
addition, IL-1 receptor antagonists (RA) such as anakinra bind to
IL-1 receptors, blocking IL-1 from binding, and have been used
successfully to prevent arthrofibrosis in small studies282,283 and
fibrosis of organs.98,284 These results suggest that IL-1 is an
important player in fibrogenesis, however, further research is
needed to investigate the efficacy of anakinra and similar products
in preventing or treating arthrofibrosis.
TNF-α antibodies
TNF-α antibodies have been shown to reduce lung fibrosis in
mice173,285 and mice lacking TNF-α signalling pathways are
protected from lung fibrosis;170 however, the use of TNF-α
antibodies in fibrogenic diseases has produced contradictory
results.285 Blocking a single key inflammatory cytokine such as
TNF-α can block the cascade of other inflammatory cytokines,
including IL-1β and IL-6,158 together with the resulting tissue
damage and ROS.285 This effect, combined with an expected
reduction in TGF-β, TGF-β receptors and collagen type I with TNF-
α blockade,286 suggests that TNF-α antibody treatment may be
useful for treating arthrofibrosis. Verjee et al.287 demonstrated that
TNF-α antibodies inhibited the contractions of myofibroblasts
taken from patients with Dupuytren’s disease, which involves
progressive fibrosis of the palm. A rat model of fatty liver disease
showed that TNF-α antibody treatment reduced inflammation and
fibrosis, as well as serum TGF-β in experimental models.285,288
In support of this, one patient on the patient website
KNEEguru241 reported that TNF-α antibody treatment was
effective for managing the pain associated with active arthrofi-
brosis. TNF-α induces peripheral pain sensitisation56,187,289 so it is
expected that TNF-α antibodies will assist in pain management.
However, the usefulness TNF-α antibody therapy for managing
arthrofibrosis in the wider patient community is unknown. TNF-α
has pleiotropic effects, and its role in organ fibrosis remains
controversial.285,286 In addition, it may have different effects in
different organs.285 The importance of TNF-α in established
fibrosis remains to be clarified, and further research is required
to understand the effectiveness of TNF-α antibodies as a
therapeutic agent for treating fibrosis.
Pathology and therapeutic outlooks for arthrofibrosis
KM Usher et al.
15
Bone Research             (2019) 7:9 
For a review of potential pharmacological therapies to treat
fibrosis see Nanthakumar et al.17
MESENCHYMAL STEM CELLS
Mesenchymal stem cells (MSCs) are able to home in on injured
tissue and differentiate into different tissue types.290 They
modulate the immune system by altering the activation and
proliferation of immune cells, and are being tested in clinical trials
for the treatment of lung fibrosis.174,291,292
Some studies have reported positive results using MSCs to treat
fibrosis of organs in mice, however, MSC treatment remains
controversial. Bone marrow-derived MSCs transform into myofi-
broblasts in rats293 and organ-resident MSC-like cells have been
shown by genetic lineage tracing to transform into myofibroblasts
and contribute to fibrosis progression in mice.107 Mice with liver
fibrosis treated with bone marrow-derived human MSCs showed
that some of the donated cells appeared to differentiate into
myofibroblasts in the liver.294,295 It is not known how closely these
cells resemble the MSC lineages used in in vitro studies.
Nonetheless, the few studies of MSCs in humans to date have
not demonstrated worsening fibrosis.296,297
It is known that MSCs can contribute to the growth of
tumours,290 but a recent small phase I clinical trial of MSCs in
the treatment of pulmonary fibrosis reported no adverse safety
outcomes.292 Different preparations of MSCs differ in their efficacy,
perhaps because of variation in their expression of anti-
inflammatory genes.298 The age and origin of MSCs may affect
the outcome of fibrosis therapy, as MSCs from different lineages
express different proteins that affect their therapeutic potential.299
MSCs from the IFP of patients with OA appear to inhibit the
production of inflammatory cytokines in vitro.300
However, MSCs from the IFP are also capable of differentiating
into fibroblasts25 in a similar wasy to MSCs from bone marrow.113
Furthermore, MSCs from the synovial membrane are positive for
the TGF-β receptor CD 105,299 raising the possibility that these
cells may induce fibrosis under inflammatory conditions. Indeed,
TGF-β is understood to be a key factor that recruits MSCs to
damaged tissue, and the demonstrated differentiation of MSCs
into myofibroblasts94 suggests that MSCs are often involved in the
pathology of fibrosis.
DIET
A number of dietary additions may assist those about to undergo
surgery to avoid arthrofibrosis, or reduce symptoms in those with
an existing condition, although data is lacking. A diet rich in
omega 3 fatty acids is recommended for inflammatory conditions
(see above in Resolvins). Capsaicin (found in chilli and peppers)
and sulphoraphane (found in cruciferous vegetables) have been
demonstrated to reverse differentiation of myofibroblasts in vivo.
Sulphoraphane has an anti-fibrosis effect via the activation of
nuclear factor erythroid 2-related 2, which may be important in
preventing fibroblast differentiation.301 A diet high in resistant
fibre is also likely to be beneficial for preventing inflammation and
fibrosis. Gut bacteria produce short-chain fatty acids from non-
digestible dietary fibre, which counter inflammation and suppress
the cleavage of protease caspase-1 and secretion of IL-18.302
In addition, consumption of soy products may help reduce the
levels of inflammatory cytokines. The breakdown products of soy
isoflavones, daidzein and genistein, are known to be antioxidant
and anti-inflammatory compounds, but their usefulness in treating
arthrofibrosis has had only limited testing in non-human animals.
Liu et al.303 found that in rabbits the topical application of
daidzein to exposed tissue during surgery reduced fibroblast
density, collagen formation and adhesions. Daidzein reduced ROS
and levels of TGF-β and when given subcutaneously to rats,
reducing lung fibrosis.150
Some of the dietary compounds mentioned above also change
epigenetic modifications, and were recently reviewed by Khan
et al.281
Vitamin D is required for immune system homoeostasis,
reducing TGF-β, suppressing the Th17 profile, and supporting
regulatory T cells that suppress autoreactive T cells.304 Vitamin D
deficiency is correlated with fibrosis of the liver and vitamin D3
inhibits the production of collagen type 1 in the liver305 and in the
lung.306 This suggests that this important vitamin may be a useful
anti-fibrotic agent.103
Fibrosis may be promoted by a reduced dietary intake of
potassium (K+) and low serum K+ levels were associated with liver
fibrosis.307 K+ efflux from cells can result from cellular damage and
the release of adenosine triphosphate.308 Upregulation of the
intermediate/small-conductance Ca2+-activated K+ channel alters
the membrane potential of cells and promotes fibrogenesis, with
effects including higher levels of Ca2+ entry into cells and
expression of Ca2+-dependant growth factor genes, cyclins and
kinases involved in cell division.309 High-intracellular levels of Ca2+
are associated with cardiac fibrosis202and KCa3.1 silencing in
animal models of renal fibrosis decreased the numbers of
myofibroblasts and attenuated the development of fibrosis.310
This result appears to be mediated via the Smad2/3 pathway,
since KCa3.1 blockade reduced levels of TGF-β1, and TGF-β1
receptor II.311
The loss of intracellular K+ also activates NLRP3 inflammasomes,
which are known to promote fibrosis. Sun et al. found that low
levels of K+ promotes vascular calcification and osteogenic
differentiation.312 This may have implications for the calcification
that sometimes occurs within ECM in arthrofibrosis.
Intermittent fasting has profound positive effects on many
health measures and can improve functional outcomes for many
diseases.313 Animal research shows that intermittent fasting is
protective against fibrosis of organs,314 and it is also known
suppress inflammation313,315 and downregulate the inflammatory
cytokines IL-1, IL-6 and TNF-α in humans.316 Intermittent fasting
suppresses the activity of NLRP3 inflammasomes,313 providing
what appears to be a cumulative anti-fibrotic effect. Intermittent
fasting can be approached in a number of ways, including
restricting calorie intake 2 days of the week, restricting food intake
to 8 h or less per day, and periods of 1 or 2 days in which there is
little or no calorie intake on a recurring basis.313 Nutrient depletion
prior to surgery can protect against damage from ischaemic
conditions.317 Intermittent fasting is also known to reduce levels
of insulin-like growth factor-1, which promotes the survival of
myofibroblasts in liver fibrosis.252
Intermittent fasting may also trigger the amino acid limitation
response, which alters immune function by regulating T- and B-
cell proliferation, activation and differentiation.318 The amino acid
L-proline is required for fibrosis, as it is a necessary pre-curser of
collagen.319 L-proline production can be upregulated by arginine
metabolism, resulting in macrophage switching and promoting
Th2 cells and fibrosis.319
OTHER TREATMENTS
Recent research suggests that injections of collagenase, a
proteolytic bacterial enzyme that specifically breaks down
collagen, can increase ROM in arthrofibrosis of the shoulder320,321
and in animal models of arthrofibrosis of the knee, however,
further research is needed to address concerns relating to
degradation of articular cartilage, ligaments and tendons.322 In
addition, the signalling effects of collagen fragments created by
cleavage also needs to be considered, as some of these fragment
have biological activity.104 However, collagenase has been
approved for Dupuytren disease, a fibroproliferative disease of
the palm.323 Collagenase in slow release nanocapsules have been
developed and tested in an animal model of skin fibrosis, showing
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sustained release over 10 days.324 This could lower the number of
doses required.
Soft tissue mobilisation techniques using tools designed to
exert shear force, break down ECM and stimulate blood flow have
been developed, and have several trademark names including
ASTYM and the Graston Technique. These tools can be applied to
the joint and may assist recovery from arthrofibrosis32,325,326 and
tendon damage,327 particularly before the ECM matures. Some
patients on the website KNEEguru report good results,241
however, there are few large well-controlled trials, and more
research is needed to determine how effective these methods
are.326
Interventions that increase tissue vascularisation may slow the
progression of fibrotic processes.13 A small study involving three
patients undergoing revision TKR for arthrofibrosis suggested that
low dose irradiation prior to surgery may result in improved
ROM.30
PATIENT PERSPECTIVES
The experiences of arthrofibrosis patients are seldom heard in the
scientific literature, and can provide useful insights into the
condition. Arthrofibrosis patients on the website KNEEguru241
show that there are a group of patients with active arthrofibrosis,
for whom surgical intervention to lyse ECM has proven to be
detrimental. Another group may have had initially detrimental
results from surgery, however, subsequent surgery led to
important improvements in symptoms. The reasons for these
significantly different outcomes are not clear, but may include the
level of inflammation, the time between surgeries, surgical
technique, rehabilitation protocols and individual predisposition
through genetic or other factors. Unfortunately, as with research
publications, these forums are largely silent on the long-term
outcomes for patients with permanent active arthrofibrosis.
Many patients believe that overly aggressive exercise rehabilita-
tion soon after surgery was detrimental to their recovery, and
strongly advocate that arthrofibrosis sufferers “listen to their
knee”, and do not push too hard to fit in with exercise regimes
and expected recovery timetables. As mentioned previously, this
fits with views expressed recently that rehabilitation should be
progressed conservatively, and based on the inflammatory
response it provokes.12,328
One patient provides a useful case study into the causes and
types of arthrofibrosis. Following bilateral TKR a 45-year-old
female immediately began intensive post-operative use of CPM
in addition to exercise rehabilitation. Initially the right knee had
restricted ROM of around 70°. After several months of intensive
daily CPM use the knee regained a functional amount of flexion
and CPM use was discontinued. The ROM on the left knee was
initially 105°, but at 2 weeks post-surgery a minor forced bending
on a CPM lacking digital control likely caused internal bleeding,
and the knee immediately lost ROM, with maximum flexion falling
to 70°. Intensive CPM use gradually increased flexion, however, the
knee remained painful and intensive CPM use was required to
maintain functional ROM.
After 5 and half months the arthrofibrosis resolved, and the
knee became fully functional without pain and with stable active
flexion of about 110°. However, 4 weeks after full resolution of
arthrofibrosis the patient became ill with suspected influenza.
Active arthrofibrosis spontaneously and permanently returned
in the left knee, with pain and difficulty maintaining active flexion
of 80°.
Several factors are significant in this history. Firstly, the patient
has one knee with residual arthrofibrosis (resolved but stiff), while
the other knee has active arthrofibrosis, triggered initially by
internal bleeding shortly after surgery. Vascular damage is known
to promote fibroblast activation.329 Secondly, after the resolution
of early symptoms influenza appears to have triggered the
permanent return of active arthrofibrosis. Many of the inflamma-
tory cytokines that are produced in response to influenza,
particularly IL-1, IL-6 and TNF-α330,331 are known to cause the
differentiation of fibroblasts into myofibroblasts103 and are
important cytokines in arthrofibrosis (see above). In addition,
influenza directly activates NLRP3 inflammasomes,332,333 which
are implicated in fibrosis. Influenza also activates biologically
inactive TGF-β,146,331 the primary driver of fibrosis. This suggests
that this virus is a significant risk factor for arthrofibrosis, with the
risk potentially higher for post-operative patients and those with
residual fibrosis.
CONCLUSION AND FUTURE DIRECTIONS
Arthrofibrosis is a fibrotic disease caused by excessive myofibro-
blast proliferation with defective apoptosis, primarily induced by
dysregulated TGF-β signalling. Once established these factors and
others, including extensive collagen cross-linking, create a
complex web of positive feedback processes that establish a
new pathological homoeostasis that maintains excessive ECM
accumulation and low-grade inflammation. These processes are
initiated by chronic low-grade or acute inflammatory conditions or
events.
Surgical lysis and removal of ECM, and MUA, remain the primary
treatments for arthrofibrosis. The surgical removal of ECM can be
beneficial, not only because it removes the physical stress and
restriction to ROM but also because it removes pro-fibrotic
mediators bound to the ECM that can fuel the cycle of ECM
formation. However, the potential benefits of surgery must be
weighed against the risks, which include increased dysregulation
of fibrogenesis in response to the surgical injury. This can result in
the rapid return of arthrofibrosis with increased severity of
symptoms. MUA also carries significant risks such as fractured
bones, torn tendons and damaged prostheses and can increase
symptom severity.
The development of a minimally invasive diagnostic tool kit that
assesses the levels of cytokines, collagen fragments and other
mediators of fibrosis in serum and synovial fluid may help to
predict which patients are at greatest risk of post-operative
arthrofibrosis. This research could provide relatively fast results
that may help prevent permanent disability for thousands.
Patients found to be at risk could receive anti-fibrotic therapies
and intensive monitoring by a rheumatologist to control
inflammation.
Early intervention to prevent fibrosis is likely to be important,14
halting the process before extensive epigenetic modifications
occur and a significant amount of ECM has formed and become
strongly cross-linked. This could potentially stop the pathological
cascade of dysregulation and positive feedback that results in
permanent active fibrosis,214 while also preventing damage to
joint structures such as cartilage and ligaments that occurs with
tissue contraction and altered biomechanics.
Future research should investigate the mechanism of potentia-
tion (memory) from previous surgeries and injuries. Elucidation of
this mechanism may indicate the best timing and most
appropriate treatment targets to prevent post-operative arthrofi-
brosis. Anti-fibrotic coatings on surgical implants may prove useful
in preventing arthrofibrosis.248 In addition, the lack of an effective
therapeutic agent to halt or reverse fibrosis after it develops
remains an issue of enormous importance for arthrofibrosis and
fibrosis of organs. Recent research shows that it is possible to
reverse fibrosis but it is still not understood how this occurs.
Until these research priorities are addressed risk factors such as
many previous surgeries, pre-existing stiffness or inflammation,
early onset OA, childhood adversity and female gender should be
considered prior to surgery. In addition, a conservative approach
to rehabilitation exercises is recommended with adjustments
made according to how the joint responds. Aspirin provides a
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useful means to both reduce inflammation and induce the
production of resolvins, and should be used in preference to other
NSAIDS where possible. Low-dose aspirin can be effective,
particularly if taken with omega 3 fatty acids. Other aspects of
diet and nutrition should also be considered. CPM may be useful
for minimising joint contractions, however, research into the use
of CPM to treat arthrofibrosis is lacking.
The different disorders that are diagnosed as arthrofibrosis need
to be clarified and defined. This includes residual arthrofibrosis
with a stiff joint, and active arthrofibrosis in which inflammatory
processes and ECM formation are continuing. Attention should be
focused on assessing levels of pain, inflammation and functional
scores. It is likely that patients with active arthrofibrosis have a
higher risk of the return of aggressive arthrofibrosis following
surgical intervention or MUA, compared to those with residual
arthrofibrosis.
The IFP and pouches within the knee provide relatively
contained spaces to trap injected therapeutic agents. This,
together with the ability to diagnose arthrofibrosis very early in
the process of ECM formation suggests that arthrofibrosis research
would be a useful testing ground for fibrosis treatments in
general. Likewise, treatments for organ fibrosis are also likely to be
useful for treating arthrofibrosis. New therapeutic targets include
epigenetic modifications, TGF-β and its downstream signalling, IL-
1β, NLRP3 inflammasomes, mast cells, substance P and hypoxia-
inducible factor-1. A number of promising therapeutic candidates
are currently available, and more are in clinical trials.17 A
combination of several targets may be needed; however, some
existing medications for treating other conditions may prove to be
useful.
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